Compare · PM vs SGTX
PM vs SGTX
Side-by-side comparison of Philip Morris International Inc (PM) and Sigilon Therapeutics Inc. (SGTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PM and SGTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PM is the larger of the two at $274.40B, about 4718.3x SGTX ($58.2M).
- PM has hit the wire 8 times in the past 4 weeks while SGTX has been quiet.
- PM has more recent analyst coverage (25 ratings vs 8 for SGTX).
- Company
- Philip Morris International Inc
- Sigilon Therapeutics Inc.
- Price
- $177.19+0.64%
- $22.53-2.57%
- Market cap
- $274.40B
- $58.2M
- 1M return
- +3.64%
- -
- 1Y return
- -1.88%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 8
Philip Morris International Inc
Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
Sigilon Therapeutics Inc.
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Latest PM
- Counterfeit Cigarettes Drive EU Illicit Market Above 10% for First Time Since 2014
- Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Philip Morris International Participates in 2026 dbAccess Global Consumer Conference; Updates 2026 Full-Year Diluted EPS Forecast for Currency and Non-Cash Impairment Only
- Philip Morris International to Host Webcast of Presentation at the 2026 dbAccess Global Consumer Conference
- SEC Form SD filed by Philip Morris International Inc
- Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Philip Morris International Announces Group CFO Succession
- PMI U.S. Expands Its Talent Pipeline and Welcomes New Class of Interns Across the Enterprise
- SEC Form SCHEDULE 13G filed by Philip Morris International Inc
- Director Combes Michel was granted 1,119 shares, increasing direct ownership by 11% to 11,643 units (SEC Form 4)
Latest SGTX
- SEC Form SC 13G/A filed by Sigilon Therapeutics Inc. (Amendment)
- SEC Form 15-12G filed by Sigilon Therapeutics Inc.
- SEC Form EFFECT filed by Sigilon Therapeutics Inc.
- SEC Form 4 filed by Flagship Ventures Fund V General Partner Llc
- Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
- SEC Form SC 13D/A filed by Sigilon Therapeutics Inc. (Amendment)
- SEC Form 4: Eli Lilly & Co bought $25,639,916 worth of shares (1,718,493 units at $14.92)
- Lilly Completes Acquisition of Sigilon Therapeutics
- SEC Form S-8 POS filed by Sigilon Therapeutics Inc.
- SEC Form S-8 POS filed by Sigilon Therapeutics Inc.